• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Everolimus

Everolimus

Product ID E8419
Cas No. 159351-69-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $61.10 In stock
5 mg $137.90 In stock
25 mg $330.80 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Everolimus is an inhibitor of mammalian target of rapamycin 1 (mTOR1) that is used clinically for its immunosuppressive activity in renal transplant recipients and is currently in clinical trials exploring its anticancer chemotherapeutic activity. In nasopharyngeal carcinoma cells, everolimus induces apoptosis and autophagy, inhibiting cell growth. In esophageal cancer cells, everolimus decreases expression of mTOR targets p70S6K and S6, increasing cell damage and decreasing cell proliferation. In animal models of experimental autoimmune uveoretinitis (EAU), everolimus decreases levels of Th1, Th2, and Th17 cytokines and increases levels of Treg cells, attenuating disease pathology. Additionally, everolimus exhibits nephroprotective benefit at low doses, decreasing adriamycin-induced proteinuria and improving renal function in animal models of nephrotic syndrome.

Product Info

Cas No.

159351-69-6

Purity

≥98%

Formula

C53H83NO14

Formula Wt.

958.22

Chemical Name

40-O-(2-hydroxyethyl)-sirolimus

IUPAC Name

Dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0 hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

Synonym

Certican, SDZ RAD, 40-O-(2-hydroxyethyl)-rapamycin, RAD001

Melting Point

95-110°C

Solubility

Insoluble in water. Soluble in DMSO (30mg/mL), ethanol (7 mg/mL).

Appearance

White to off white powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

E8419 MSDS PDF

Info Sheet

E8419 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Sendur MA, Zengin N, Aksoy S, et al. Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin. 2014 Jan;30(1):75-87. PMID: 24050600.

Cai Y, Xia Q, Su Q, et al. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells. Int J Mol Med. 2013 Apr;31(4):904-12. PMID: 23426850.

Hennig M, Bauer D, Wasmuth S, et al. Everolimus improves experimental autoimmune uveoretinitis. Exp Eye Res. 2012 Dec;105:43-52. PMID: 23059401.

Ramadan R, Faour D, Awad H, et al. Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome. Nephrol Dial Transplant. 2012 Jun;27(6):2231-41. PMID: 22036940.

Wang ZG, Fukazawa T, Nishikawa T, et al. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncol Rep. 2010 Apr;23(4):1167-72. PMID: 20204306.

Kahan BD, Koch SM. Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care. 2001 Aug;7(4):242-50. PMID: 11571421.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • P6800

    Pravastatin Lactone

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • D3322

    Diflunisal

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • N7604

    Naltriben

    δ2OR antagonist.

    ≥95%
  • B8276

    Butyric Acid Sodium

    HDAC inhibitor, RNA splicing modulator.

    ≥98%
  • K1978

    Ketorolac Tromethamine

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • A016493

    4-Aminopyrimidine

    Building block

    ≥98%
  • B3272

    Bis(3,5-dibromosalicyl) Fumarate

    Aspirin analog; hemoglobin chain cross-linker.<...

    ≥91%
  • R2811

    Recombinant HIV-1 gp-41

    Recombinant HIV glycoprotein antigen fragment.<...

    ≥95%
  • K9858

    Kyotorphin

    Opioid neuropeptide; kyotorphin agonist.

    ≥95%
  • B030962

    BAY-1251152

    Inhibitor of PTEFb/CDK9.

    ≥98%
  • C5773

    Cortistatin-14

    Endogenous neuropeptide, somatostatin analog; s...

    ≥95%
  • M3321

    Mifepristone

    Synthetic steroid, contraceptive; PR and glucoc...

    ≥98%
  • L5822

    Lofexidine Hydrochloride

    α2-adrenergic agonist.

    ≥98%
  • E8401

    Evacetrapib

    Cholesterol ester transfer protein inhibitor.

    ≥98%
  • E6814

    Erdosteine

    Thiol derivative, antioxidant.

    ≥98%
  • S7618

    StemRegenin 1 Hydrochloride

    AhR antagonist.

    ≥98%
  • D3353

    Diminazene Aceturate

    Diamidine; ACE2 activator, DNA polymerase inhib...

    ≥98%
  • A480010

    AM630

    CB2 receptor antagonist.

    ≥97%
  • T6811

    Tranexamic Acid

    Plasminogen inhibitor.

    ≥98%
  • I7341

    Isoniazid

    Nicotinic acid derivative; InhA inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only